Survival in Patients with Glioblastoma Receiving Valganciclovir

New England Journal of Medicine
September 4, 2013
Cited by 189Open Access
Full Text

Abstract

A retrospective analysis of selected patients with glioblastoma who received treatment for cytomegalovirus with their anticancer treatment showed surprisingly good 2-year survival. A randomized trial is needed.


Related Papers

No related papers found

Powered by citation graph analysis